Background: Korean Red Ginseng (KRG; Panax ginseng Meyer) is a widely used medicinal herb known to exert various immune modulatory functions. KRG and one of its purified components, ginsenoside Rg3, are known to possess anti-inflammatory activities. How they impact helper T cell-mediated responses is not fully explored. In this study, we attempted to evaluate the effect of KRG extract (KRGE) and ginsenoside Rg3 on Th1 cell responses. Methods: Using well-characterized T cell in vitro differentiation systems, we examined the effects of KRGE or enhanced Rg3 on the Th1-inducing cytokine production from dendritic cells (DC) and the naïve 
Introduction
Korean Red Ginseng (KRG) is heat-processed White ginseng (the root of Panax ginseng Meyer); it has better pharmacological activities and has enhanced preservation efficacy and safety [1, 2] . Accumulating evidence clearly demonstrates the beneficial effects of KRG extract (KRGE) on enhancing immune functions [3, 4] as well as ameliorating diverse diseases including diabetes [5, 6] , colitis [7, 8] , cancer [7, 9] , atherosclerosis [10, 11] , neurodegenerative disease [12, 13] , and stress [14] .
Various pharmacological components are examined in ginseng extract such as acidic polysaccharides, ginsenosides, polyacetylenes, and polyphenolic compounds [15] . Among them, ginsenosides have been thought to be important ingredients, which provide ginseng's pharmacological and biological activities [12, 16, 17] . Multiple types of ginsenosides are present in ginseng extracts (e.g., Rbs, Rcs, Rd, Re, Rfs, Rgs); among them, ginsenoside Rg3 (40.1%), Rg5 (18.6%), and Rh2, Rk1 (5.73%), and Rs4 are uniquely found in Red ginseng [18, 19] . In particular, Rg3 has been reported to prevent or ameliorate diseases, such as chronic fatigue [20] , diabetes [21] , and tumor [22] .
On the other hand, dendritic cells (DC) are professional antigenpresenting cells (APCs) that connect innate and adaptive immune responses [23, 24] . Once DCs uptake antigens, DCs produce proinflammatory cytokines, increase the co-stimulatory molecules, and subsequently present antigens to T cells [23e25] . Of note, ginseng extract or ginsenosides have been shown to modulate the maturation and function of DCs. For instance, ginseng saponins or ginseng metabolites enhanced DC maturation markers, such as CD80, CD83, CD86, and MHCII [26, 27] . In addition, ginseng activated DCs to produce IL-1 and TNFa, and ginseng-primed DCs improved the CD4 þ T cell proliferations and the interferon gamma (IFNg) production [27, 28] . However, several reports have shown opposite effects of ginseng on DCs including the diminished production of IL-12 and TNF-a and the inhibition of CD40 and CD86 expression [29, 30] . The preventive and therapeutic effects of whole ginseng extract or ginsenosides on various immune disorders have been reported in several studies [6, 8, 13, 31] ; however, the effect of ginsenosides on the development of each subset of T cells remains incompletely understood. In this present study, we investigated the influence of ginsenoside Rg3 on Th1 cell responses in vitro and in vivo. Our findings demonstrate that Rg3 attenuates the differentiation of IFNg þ CD4 þ T cell in vitro and in vivo.
Materials and methods

Ethics statement
All vertebrate animal experiments were approved by the Institutional Animal Care and Use Committee of Seoul National University (protocols SNU-170120-1) and were conducted in accordance with the guidelines of Seoul National University for the care and use of laboratory animals. All surgeries were performed under isoflurane anesthesia (Piramal Critical Care, Inc., PA, USA).
KRGE and enhanced Rg3
KRGE and enhanced Rg3 were provided by Korea Ginseng Corporation (Seoul, South Korea). Enhanced Rg3 is one of the KRGE that has been enriched in Rg3 content. In KRGE and enhanced Rg3, totally 1.94% and 5.425% of ginsenosides are contained, respectively. In case of KRGE, ginsenosides Rg1 (0.071%), Re (0.093%), Rf (0.121%), Rh1 (0.078%), Rg2(s) (0.192%), Rg2(r) (0.129%), Rb1 (0.462%), Rc (0.241%), Rb2 (0.183%), Rd (0.089%), Rg3(s) (0.214%), and Rg3(r) (0.091%) are included. In addition, enhanced Rg3 consists of nine ginsenosides: Rf (0.105%), Rh1 (0.294%), Rg2(s) (0.294%), Rb1 (0.290%), Rc (0.097%), Rb2 (0.197%), Rd (0.137%), Rg3(s) (3.373%), and Rg3(r) (0.638%). Enhanced Rg3 also has 4.77% of arginyl-fructosyl-glucose and 4.125% of acidic polysaccharides. The phytochemical study data was provided by The Korean Society of Ginseng. The KRGE and enhanced Rg3 were dissolved in sterilized water.
Cell cytotoxicity
To determine the proper doses of KRGE or enhanced Rg3, the 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) reduction assay was performed. Briefly, increasing doses of KRGE (0 mg/mL, 31.25 mg/mL, 62.5 mg/mL, 125 mg/mL, 250 mg/mL, and 500 mg/mL) and enhanced Rg3 (0 mM, 25 mM, 50 mM, 100 mM, and 200 mM) were treated with bone marrow-derived DCs for 24 h; the cells were then incubated with MTT solution (final conc. 500 mg/ mL) (Life Technologies, Carlsbad, CA, USA) for 4 h at 37 C. After incubation, MTT solution was removed and dimethyl sulfoxide was added. The absorbance was measured at 540 nm by a microplate reader (Bio-Rad, Hercules, CA, USA). Absorbances were normalized to untreated control to calculate cell viability.
Mice and in vivo experimental design
Ten C57BL/6 female mice aged 5 wk were purchased from Orient Bio (Seongnam-si, Gyeonggi, South Korea). These mice were divided into two groups, a control group and an enhanced Rg3-treated group. Mice were orally administered with distilled water (control) or enhanced Rg3 (0.03 gram/kg) every other day. After 4 wk, gut-draining mesenteric lymph nodes (MLNs), Peyer's patches (PPs), and large intestines were isolated for analysis of T cell subsets. 
Generation of bone marrow-derived DCs
Enzyme-linked immunosorbent assay
IL-1b, 6, 12p70, 12p40, and TNFa in the culture supernatants of naïve T cell differentiation were quantified by enzyme-linked immunosorbent assay, according to the manufacturer's instructions (eBioscience, San Diego, CA, USA).
Real-time polymerase chain reaction
Total RNA from cells was isolated by TRIzol reagent (Ambion, CA, USA), and cDNA was synthesized with a cDNA Synthesis kit (Thermo Fisher Scientific Inc., New York, NY, USA). Relative gene expression levels were evaluated using SYBR Green (Bio-Rad) on ABI 7500 Fast Real-Time Polymerase Chain Reaction Systems (Applied Biosystems, Singapore). Target genes were normalized to the b-actin level in each sample. Primer sets for genes were synthesized at Cosmogenetech (Seoul, South Korea):
antisense, 5 0 -TAAAACGCAGCTCAGTAACAGTCCG-3 0 ).
Flow cytometry
Cells were incubated for 3e4 h with 100 ng/mL of PMA, 1 mM of ionomycin (all from Sigma), Brefeldin A and Monensin (all from eBioscience). After washing cells with cold PBS containing 1.5% FBS, the cells were stained with APC-Cy7-conjugated anti-CD4 mAb (eBioscience) for surface staining. Cells were then washed and stained with PerCp-Cy5.5-conjugated anti-IFNg mAb, APCconjugated anti-IL-17 mAb (all from BioLegend, San Diego, CA, USA), and Phycoerythrin (PE)-conjugated anti-T-bet mAb (eBioscience) after incubation with fixation/permeabilization buffer (eBioscience) for 30 min at 4 C (all from BioLegend). The cells were analyzed by flow cytometer, FACSVerse flow cytometer (BD Bioscience). Data were analyzed with FlowJo (TreeStar, Ashland, OR, USA).
Preparation of lamina propria cells
Large intestines were cut into 1 cm slices, and epithelium was removed by stirring in RPMI-1640 containing 1mM EDTA (Gibco) for 30 min and 2% FBS at 37 C (twice). After washing the gut pieces with pre-warmed PBS at least five times, they were cut into 1e2 mm and stirred into RPMI-1640 containing 2% FBS, 10 U/mL collagenase IV (Gibco), and 5 U/mL DNase I (Bio Basic Inc., Amherst NY, USA) for 30 min at 37 C (twice). After incubation, the suspension was filtered through a 100 mm-pore nylon mesh (Small Parts Inc., FL, USA). The lymphocytes were purified by a 44%/70% Percoll (Pharmacia, Uppsala, Sweden) gradient.
Statistical analysis
All experiments were performed two to four times. Statistical analysis was conducted with mean AE standard error of the mean by unpaired two-tailed Student t test with Prism Graphpad 5.0 (GraphPad Software Inc., La Jolla, CA, USA).
Results and discussion
KRGE inhibits the pro-inflammatory cytokines produced by DCs
Previous studies have demonstrated that ginseng modulates immune responses and prevents immune disorders. The inhibitory efficacy of Red ginseng extracts on inflammation has been suggested to be better than that of White ginseng extracts [12, 17, 32] . However, the function of ginseng or its components to the differentiation of helper T cell subsets has been incompletely understood. As a first step to explore the immune modulatory functions of KRGE on helper T cell responses, we determined the effects of KRGE on the production of cytokines from DCs since they play an essential role in determining the type of effector T cells by acting as "signal 3" during the T cells differentiation [23e25] . In order to determine the proper dose of KRGE in vitro experiment, we conducted cell viability assay by MTT. The MTT reduction assay showed no reduction in cell viability under 250 mg/mL (Fig. S1A) . On the basis of this result, we used KRGE at the concentration of 250 mg/mL. To investigate the effect of KRGE on the production of LPS-induced inflammatory cytokines, we stimulated bone marrowderived DCs by LPS in the presence or absence of KRGE and measured the amounts of pro-inflammatory cytokines from DCs including IL-1b, IL-6, IL-12, IL-23, and TNFa [24, 33] . As shown in Fig. 1 , KRGE itself had little role in inducing the production of proinflammatory cytokines from DCs. On the other hand, addition of KRGE slightly but significantly inhibited the production of IL-6, IL-10, IL-12p40, and TNFa induced by LPS (Fig. 1BeF) . By contrast, the production of LPS-induced IL-1b from DCs was slightly increased by KRGE (Fig. 1A) . Since fermented White ginseng extracts (similar to Red ginseng extracts) has been shown to inhibit the production of dextran sodium sulfate-or LPS-induced IL-6, TNF-a, and IL-12p40 from macrophages by downregulating NFkB [34] , it is feasible to surmise that the KRGE-mediated inhibition of IL-6, IL-12p40, and TNF-a from DCs might be also associated with NFkB activity. KRGE contains different type of saponins (ginsenosides) and nonsaponins including ginsan, polysaccharide, protopanaxadiol, and protopanaxatriol [35] . The saponins and non-saponins of ginseng reportedly have opposite effects in IL-1b production. The saponin fractions of ginseng extract attenuated IL-1b maturation, whereas non-saponin fractions or water extract of ginseng stimulated IL-1b production [36, 37] . In contrast to these results, the saponin fraction of KRGE has shown to enhance the IL-1b expression induced by oxazolone. However, the constituent ginsenosides, such as Rf, Rg3, and Rh2, effectively reduced the expression of IL-1b [38] . These results demonstrate that non-saponins and several types of saponins contained in KRGE could increase the production of IL-1b from DCs. Of note, we observed that addition of KRGE significantly downregulated the production of IL-12 from DCs induced by LPS (Fig. 1D) . IL-12 induces the phosphorylation of signal transducer and activator of transcription 4 (STAT4), leading to the naïve CD4 þ T cells into the Th1 cell lineage program including induced T-bet expression [39, 40] . Since KRGE decreased production of IL-12 from DCs, we hypothesized that KRGE might impact the Th1 cell differentiation.
KRGE suppresses DC-mediated Th1 cells differentiation
To determine the effect of KRGE on the Th1 cells differentiation, we employed a well-established DC-T cell co-culture in vitro system in which the addition of soluble anti-CD3 and LPS triggers the differentiation of IFNg-producing Th1 cells from the naïve CD4 þ T cells [41] . In this DC-T cell system, we observed that the addition of KRGE moderately decreased the frequency of IFNg-producing Th1 cells ( Fig. 2A) , likely due to the reduced IL-12 production from DCs. Accordingly, the production of IFNg from T cells was significantly diminished (Fig. 2B ).
To determine if KRGE has any direct effects on T cell during Th1 differentiation, we employed a DC-free Th1 cell differentiation condition by stimulating naïve CD4 þ T cells. Under this condition, KRGE also exerted a slightly but significant reduction in the frequency of IFNg þ CD4 þ T cells and the amount of IFNg from T cells (Fig. 2C and D) , although the magnitude of suppression was weaker than the DC-T cell co-culture system. These results together strongly demonstrate that KRGE inhibits the Th1 cells differentiation in vitro by decreasing the IL-12 production and also by directly affecting T cells. Since Th1 cells are well-known as a crucial player for the pathogenesis in autoimmune diseases such as colitis [42] and EAE [43] , the use of KRGE might be effective in ameliorating Th1-mediated immune disorders.
Enhanced Rg3 negatively regulates DC-mediated Th1 cell differentiation
Since Rg3 is a major gensenoside in KRGE [18, 19] , we next questioned if enhanced Rg3 plays any role in the KRGE-induced suppression of Th1 cell differentiation. First, we investigated the cell toxicity of enhanced Rg3 on bone marrow DCs, and the MTT reduction assay showed that the concentrations less than 100mM have no effect on cell viability (Fig. S1B) . We next examined the role of enhanced Rg3 in Th1 cell differentiation. Similar to KRGE, enhanced Rg3 significantly suppressed LPS-induced production of IL-12p70 and IL-6 from DCs ( Fig. 3A and Fig. S2A ). Moreover, enhanced Rg3 also significantly suppressed the production of IL12p40 (Fig. 3A) , which differed from the effect of KRGE shown in Fig. 1 . Unlike KRGE, enhanced Rg3 slightly increased the production of IL-10 ( Fig. 3A) , which is known to prevent the pathological Th1 cell responses and decrease IL-1b (Fig. S2B ) [44] . Consistent with this observation, addition of enhanced Rg3 significantly reduced DC-mediated Th1 cell differentiation and the production of IFNg from T cells (Fig. 3B and C) . We next examined the effects of enhanced Rg3 on the differentiation of Th1 cell in a DC-free condition and observed that enhanced Rg3 also significantly suppressed Th1 cell differentiation ( Fig. 3D and E) . We next sought to investigate the mechanism of enhanced Rg3-mediated inhibition of Th1 cell differentiation. As depicted in Fig. 4A , the addition of enhanced Rg3 remarkably decreased the frequencies of T-bet þ and IFNg þ CD4 þ T cells in a dose-dependent manner. The suppression of IFNg expression by enhanced Rg3 was found to be more sensitive than that of T-bet. In parallel with these protein data, the mRNA expression levels of Ifng, Tbx21, and Eomes (encoding Eomesodermin [45] ) were lower in enhanced Rg3-treated T cells in a dose-dependent manner (Fig. 4B) . Since STAT4 is a crucial transcription factor for Th1 cell differentiation [46, 47] 
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In the presence of Rg3 the phosphorylation of STAT4 in T cells. These findings together indicate that enhanced Rg3 inhibits Th1 cell differentiation via at least two different modes of action by suppressing the production of Th1-promoting IL-12 in DCs and also by inhibiting IL-12-mediated activation of the Th1 cell program in T cells.
Enhanced Rg3 controls Th1 cell population in the gut
Common microbiota in the intestinal lumen provides high density of PAMPs [48, 49] inflammation [50, 51] . [52, 53] . Neutralization of IFNg as well as deficiency of T-bet significantly ameliorates the induction of experimental colitis in animal models [42] . Moreover, anti-p40 neutralizing antibodies (e.g., ustekinumab and briakinumab) showed a moderate clinical benefit in patients with CD [54e56]. Clinical trial of ustekinumab in Phase 3 moderated the severity of CD who had failed anti-TNF antibody treatment. In addition, anti-p40 antibodies also showed clinical benefits in patients with active CD of Phase 2. These clinical efficacies demonstrate that the blockade of p40 could be a potential therapeutic strategy. Since enhanced Rg3 inhibits the differentiation of Th1 cells as well as the production of IL12p40, our findings suggest that enhanced Rg3 might be effective in ameliorating intestinal inflammatory diseases in humans including CD.
Conclusions
In summary, our findings demonstrate that enhanced Rg3 has a profound inhibitory effect on Th1 cell differentiation. This regulatory effect seems to be mediated not only by the inhibition of IL-12 production from DCs but also by directly affecting Th1 cell program in T cells, such as the downregulation of T-bet and eomesodermin. In particular, oral administration of enhanced Rg3 significantly reduced the frequency of Th1 cells in the gut, suggesting that enhanced Rg3 might be effective for the treatment of Th1-mediated inflammatory diseases in the gut.
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